Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India-based drugmaker Lupin has entered into an agreement with Polish biopharmaceutical firm Celon Pharma to jointly develop and market fluticasone/salmeterol dry powder inhaler (DPI) product, a generic version of GlaxoSmithKline's (GSK) asthma drug Advair Diskus.
Subscribe to our email newsletter
Under the deal, Celon will supply the product to Lupin, which will be responsible for its commercialization in the US, Canada, Mexico and other key markets.
GSK’s Advair Diskus had global sales of more than $7bn as of last fiscal year.
Lupin CEO Vinita Gupta said: "We are very pleased to partner with Celon given their experience in the development and manufacturing of fluticasone/salmeterol DPI in Europe.
"This coupled with Lupin’s expertise in inhalation product development and commercialization in the US and other markets will accelerate the development of generic Advair Diskus for global markets.
"We look forward to providing access to high quality, affordable fluticasone/salmeterol DPI as part of our strategy to deliver inhaled products to key markets."
According to Lupin, this partnership is an important landmark in its efforts to evolve its global inhalation pipeline.